M Luster

Summary

Country: Germany

Publications

  1. ncbi request reprint Impact of 131I diagnostic activities on the biokinetics of thyroid remnants
    Michael Lassmann
    Klinik und Poliklinik für Nuklearmedizin der Universität Würzburg, Wurzburg, Germany
    J Nucl Med 45:619-25. 2004
  2. ncbi request reprint 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer
    L S Freudenberg
    Department of Nuclear Medicine, University of Duisburg Essen, Essen, Germany
    Exp Clin Endocrinol Diabetes 115:690-3. 2007
  3. ncbi request reprint Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Acta Oncol 45:1018-30. 2006
  4. ncbi request reprint Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Germany
    Thyroid 15:1147-55. 2005
  5. ncbi request reprint Thyroid cancer in childhood: management strategy, including dosimetry and long-term results
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Germany
    Hormones (Athens) 6:269-78. 2007
  6. ncbi request reprint rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Josef Schneider Str 2, 97080 Wurzburg, Germany
    Endocr Relat Cancer 12:49-64. 2005
  7. doi request reprint Guidelines for radioiodine therapy of differentiated thyroid cancer
    M Luster
    Department of Nuclear Medicine, University of Wurzburg, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Eur J Nucl Med Mol Imaging 35:1941-59. 2008
  8. ncbi request reprint Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Eur J Nucl Med Mol Imaging 30:1371-7. 2003
  9. ncbi request reprint Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma
    M Luster
    Department of Nuclear Medicine, University of Wuerzburg, Germany
    J Clin Endocrinol Metab 85:3640-5. 2000
  10. ncbi request reprint Radioiodine therapy of metastatic lesions of differentiated thyroid cancer
    M Luster
    Department of Nuclear Medicine, University of Ulm, Albert Einstein Allee 23, Ulm, Germany
    J Endocrinol Invest 35:21-9. 2012

Detail Information

Publications42

  1. ncbi request reprint Impact of 131I diagnostic activities on the biokinetics of thyroid remnants
    Michael Lassmann
    Klinik und Poliklinik für Nuklearmedizin der Universität Würzburg, Wurzburg, Germany
    J Nucl Med 45:619-25. 2004
    ..Stunning may play a major role in reducing the therapeutic efficacy of high (131)I activities given for ablation therapy...
  2. ncbi request reprint 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer
    L S Freudenberg
    Department of Nuclear Medicine, University of Duisburg Essen, Essen, Germany
    Exp Clin Endocrinol Diabetes 115:690-3. 2007
    ..Aim of our study is to determine safety and informativeness of 124I-PET/CT dosimetry in DTC patients<or=18 yrs old...
  3. ncbi request reprint Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Acta Oncol 45:1018-30. 2006
  4. ncbi request reprint Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Germany
    Thyroid 15:1147-55. 2005
    ..In conclusion, hypothyroidism secondary to withdrawal causes important morbidity, safety risks, and productivity impairment. rhTSH avoids these drawbacks at roughly equivalent societal cost to that of withdrawal...
  5. ncbi request reprint Thyroid cancer in childhood: management strategy, including dosimetry and long-term results
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Germany
    Hormones (Athens) 6:269-78. 2007
    ..These considerations have led to individualized "tailored" therapeutic approaches based on prior risk stratification. This article mainly deals with novel nuclear medicine concepts for dosing regimens in radioiodine therapy...
  6. ncbi request reprint rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Josef Schneider Str 2, 97080 Wurzburg, Germany
    Endocr Relat Cancer 12:49-64. 2005
    ....
  7. doi request reprint Guidelines for radioiodine therapy of differentiated thyroid cancer
    M Luster
    Department of Nuclear Medicine, University of Wurzburg, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Eur J Nucl Med Mol Imaging 35:1941-59. 2008
    ....
  8. ncbi request reprint Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Eur J Nucl Med Mol Imaging 30:1371-7. 2003
    ..It is quite possible that "stunning" from the radioiodine administered in the initial uptake study inhibited the subsequent uptake of radioiodine by the remnant lesions in the second uptake study...
  9. ncbi request reprint Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma
    M Luster
    Department of Nuclear Medicine, University of Wuerzburg, Germany
    J Clin Endocrinol Metab 85:3640-5. 2000
    ..This therapeutic indication extends the clinical potential of this new agent, already demonstrated to be effective for use with 131I for diagnostic purposes...
  10. ncbi request reprint Radioiodine therapy of metastatic lesions of differentiated thyroid cancer
    M Luster
    Department of Nuclear Medicine, University of Ulm, Albert Einstein Allee 23, Ulm, Germany
    J Endocrinol Invest 35:21-9. 2012
    ..In this review, we will address the literature pertaining to the latest developments in the field of 131I therapy of advanced DTC and we will give an overview of the state of the art regarding patient preparation, dosimetry, and therapy...
  11. ncbi request reprint Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131
    C Reiners
    Nuclear Medicine Clinic, University of Wurzburg, Germany
    J Endocrinol Invest 22:17-24. 1999
    ..Ongoing dosimetric research eventually may provide more specific guidance regarding radioiodine activities for diagnostic, and, particularly, therapeutic purposes, with the use of rhTSH...
  12. ncbi request reprint Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995
    Jamshid Farahati
    Department of Nuclear Medicine, University of Wuerzburg, Germany
    Thyroid 14:141-7. 2004
    ..A population-based registry (PBR) in Lower Frankonia in southern Germany was conducted to evaluate the changes of incidence and prognosis of thyroid carcinoma (TC) in this area...
  13. doi request reprint Calcium stimulated calcitonin measurement: a procedural proposal
    F A Verburg
    Departments of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Exp Clin Endocrinol Diabetes 121:318-20. 2013
    ..In this paper we propose a procedure for calcium stimulated calcitonin measurement based on our experiences. Furthermore we will briefly point out the limitations of this method with regard to available data in literature...
  14. ncbi request reprint Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound
    P Andermann
    Department of Nuclear Medicine, University of Wurzburg, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Nuklearmedizin 46:1-7. 2007
    ..While known to be limited, the accuracy and precision of two-dimensional (2D) US thyroid volume measurement have not been thoroughly characterized...
  15. ncbi request reprint The use of dosimetry in the treatment of differentiated thyroid cancer
    M Lassmann
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Q J Nucl Med Mol Imaging 55:107-15. 2011
    ..Finally, a new concept for potentially determining patient-specific radiation sensitivity using blood dosimetry is introduced...
  16. doi request reprint Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study
    Markus Luster
    Department of Nuclear Medicine, University of Wurzburg, 97080 Wurzburg, Germany
    J Clin Endocrinol Metab 94:3948-53. 2009
    ..Although recombinant human TSH (rhTSH) is widely used in differentiated thyroid cancer (DTC) to aid diagnostic follow-up procedures and radioiodine thyroid remnant ablation, almost all clinical investigation was in adults...
  17. ncbi request reprint Recombinant human thyrotropin: safety and quality of life evaluation
    C Reiners
    Department of Nuclear Medicine, University Hospital Wuerzburg, Oberduerrbacherstrasse 6, Wuerzburg, Germany
    J Endocrinol Invest 35:30-5. 2012
    ..Last but not least, more convenient scheduling of patients and shorter duration of time to be spent in the radioprotective ward are further arguments in favor of rhTSH...
  18. doi request reprint (131)I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies
    F A Verburg
    University of Ulm, Department of Nuclear Medicine, Germany
    Nuklearmedizin 50:93-9; quiz N20. 2011
    ..A potentially increased risk of malignancies due to this therapy is however still subject of debate...
  19. doi request reprint Reference ranges for analytes of thyroid function in children
    F A Verburg
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Horm Metab Res 43:422-6. 2011
    ..During very early life, values of these analytes range widely, making it challenging to interpret measurements in infants, and, especially, newborns...
  20. doi request reprint The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life
    C Dueren
    Department of Nuclear Medicine, University of Wuerzburg, Wuerzburg, Germany
    Exp Clin Endocrinol Diabetes 118:513-9. 2010
    ..Second aim was to determine a clear patient preference for the one method or the other...
  21. ncbi request reprint Low-risk differentiated thyroid carcinoma patients still deserve I-131 remnant ablation after total thyroidectomy
    F A Verburg
    Department of Nuclear Medicine, University of Wuerzburg, Wuerzburg, Germany
    Minerva Chir 65:95-100. 2010
    ..In this review various staging systems for classifying patients as "very low risk" "low risk" or "high risk" are discussed, followed by an overview of why I-131 ablation remains an eminently sensible idea in "low risk" patients...
  22. doi request reprint [Malignant goiter--thyroid cancer]
    Chr Reiners
    Klinik und Poliklinik fur Nuklearmedizin, Universitat Wurzburg
    Dtsch Med Wochenschr 133:2215-28; quiz 2229-30. 2008
  23. ncbi request reprint Evaluation of an internet-based e-learning module to introduce nuclear medicine to medical students: a feasibility study
    Stefanie Diessl
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Nucl Med Commun 31:1063-7. 2010
    ..Aim: To evaluate the additional educational value of a voluntary e-learning module in a nuclear medicine course for third-year medical students...
  24. doi request reprint No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer
    Frederik Anton Verburg
    Department of Nuclear Medicine, University of Wurzburg, Oberdurrbacher Strasse 6, Wurzburg, 97080, Germany
    Eur J Nucl Med Mol Imaging 37:276-83. 2010
    ....
  25. doi request reprint Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience
    Frederik A Verburg
    Department of Nuclear Medicine, University of Wurzburg, Oberdurrbacher Strasse 6, 97080, Wurzburg, Germany
    Eur J Nucl Med Mol Imaging 37:896-903. 2010
    ..We sought to evaluate the safety and effectiveness in everyday tertiary referral centre practice of treating advanced DTC with high (131)I activities chosen primarily based on the results of dosimetry following this SOP...
  26. doi request reprint A comparison of prognostic classification systems for differentiated thyroid carcinoma
    Frederik A Verburg
    University of Wurzburg, Department of Nuclear Medicine, Wurzburg, Germany
    Clin Endocrinol (Oxf) 72:830-8. 2010
    ..To identify and compare prognostic classification systems based on basic tumour characteristics that were developed and/or validated for differentiated thyroid carcinoma (DTC)...
  27. doi request reprint Dosimetry and thyroid cancer: the individual dosage of radioiodine
    Michael Lassmann
    Department of Nuclear Medicine, University of Wurzburg, Oberdurrbacher Strasse 6, D 97080 Wurzburg, Germany
    Endocr Relat Cancer 17:R161-72. 2010
    ..The limitations of treatments aiming at high absorbed doses are addressed as well as the doses to normal organs. Finally, new concepts for further elaborating the potential of thyroid cancer treatment using (131)I are introduced...
  28. doi request reprint EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy
    Michael Lassmann
    Department of Nuclear Medicine, University Hospital Wurzburg, Wurzburg, Germany
    Eur J Nucl Med Mol Imaging 35:1405-12. 2008
    ....
  29. doi request reprint Intratracheal growth of recurrent benign goiter
    Frederik A Verburg
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Thyroid 19:1009-11. 2009
    ..Intratracheal goiter manifestations caused by ectopic thyroid tissue have occasionally been reported. We report a 42-year-old female who had undergone thyroid surgery twice, which had caused unilateral recurrent laryngeal nerve palsy...
  30. doi request reprint Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma
    Heribert Hänscheid
    Department of Nuclear Medicine, University of Wurzburg, Wurzburg, Germany
    Endocr Relat Cancer 16:1283-9. 2009
    ....
  31. doi request reprint Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases
    Frederik A Verburg
    Department of Nuclear Medicine, Wurzburg University, Wurzburg, Germany
    Eur J Endocrinol 160:619-24. 2009
    ..The aim of this study was to investigate whether there are differences in tumour-specific survival if initial staging is accounted for...
  32. doi request reprint Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma
    Frederik A Verburg
    Department of Nuclear Medicine, University Clinic Würzburg, University of Wurzburg, Wurzburg, Germany
    Clin Endocrinol (Oxf) 71:291-7. 2009
    ..To study the relationship between primary tumour size and the risk of advanced disease features (multifocal or locally invasive disease, lymph-node or distant metastases) in differentiated thyroid carcinoma (DTC)...
  33. doi request reprint Radio-iodine therapy in differentiated thyroid cancer: indications and procedures
    Christoph Reiners
    Department of Nuclear Medicine, University of Wurzburg, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Best Pract Res Clin Endocrinol Metab 22:989-1007. 2008
    ..The standard approach to preparation for 131I therapy in patients with metastases is endogenous hypothyroidism after thyroid hormone withdrawal...
  34. ncbi request reprint Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal
    Heribert Hänscheid
    Klinik und Poliklinik fur Nuklearmedizin, Universitat Wurzburg, D 97080 Wurzburg, Germany
    J Nucl Med 47:648-54. 2006
    ..7 GBq (131)I in differentiated thyroid cancer after stimulation with recombinant human TSH (rhTSH) or by thyroid hormone withdrawal (THW) are presented...
  35. ncbi request reprint Diagnostic imaging work up in multi-nodular goiter
    M Luster
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    Minerva Endocrinol 35:153-9. 2010
    ..We review the spectrum of diagnostic tests and provide some recommendations regarding (nuclear medicine) therapy...
  36. doi request reprint Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma
    Markus Luster
    Department of Nuclear Medicine, University of Ulm, Germany
    Thyroid 20:527-33. 2010
    ..The aim of this study was therefore to test the hypothesis that combined (18)F-DOPA PET/CT more accurately detects MTC lesions than each modality does alone...
  37. doi request reprint Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma
    Markus Luster
    Department of Nuclear Medicine, University of Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany
    Eur J Nucl Med Mol Imaging 37:484-93. 2010
    ..The aim of this study was to investigate whether combined (18)F-DOPA PET/CT more accurately detects and localizes PHEO lesions than does each modality alone...
  38. ncbi request reprint A novel thyroid phantom for ultrasound volumetry: determination of intraobserver and interobserver variability
    S Schlögl
    Department of Nuclear Medicine, Julius Maximilians University, Wurzburg, Wurzburg, Germany
    Thyroid 16:41-6. 2006
    ....
  39. pmc Expanding indications for recombinant human TSH in thyroid cancer
    Bryan R Haugen
    Thyroid 18:687-94. 2008
  40. ncbi request reprint Real time RT-PCR analysis of thyroglobulin mRNA in peripheral blood in patients with congenital athyreosis and with differentiated thyroid carcinoma after stimulation with recombinant human thyrotropin
    Sarah Kaufmann
    Institut für Experimentelle Endokrinologie, Charite, Universtätsmedizin Berlin, 10117 Berlin, Germany
    Endocr Regul 38:41-9. 2004
    ..As a possible diagnostic alternative, we tested a real time RT-PCR protocol to determine Tg mRNA levels in peripheral blood...
  41. ncbi request reprint A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal
    Pamela R Schroeder
    Johns Hopkins Medical Institutions, Division of Endocrinology and Metabolism, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 91:878-84. 2006
    ..Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal...
  42. ncbi request reprint Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer
    Michael Lassmann
    J Nucl Med 46:899. 2005